Oral semaglutide offers the same GLP-1 receptor agonist benefits without the need for a weekly shot
Nonfatal myocardial infarction occurred in 2.3% of patients treated with oral semaglutide and 1.9% treated with placebo (HR 1.18, 95% CI 0.731.90), nonfatal stroke occurred in 0.8% versus 1.0% treated with placebo (HR 0.74, 95% CI 0.351.57), and death from cardiovascular causes occurred in 0.9% versus 1.9% treated with placebo (HR 0.51, 95% CI 0.310.84)
For someone with a history of diverticular disease, though, those changes carry more weight
Nike Training Club App (Free): Offers 5-30 minute workoutstry Starter Strength (15 min) or Cardio Kickstart (20 min)
Across the STEP trials that enrolled non-diabetic participants, mean weight loss on semaglutide 2.4 mg ranged from 14.9% (STEP 1, medication alone) to 16.0% (STEP 3, medication plus behavioral therapy) at 68 weeks [1][2]